|
|
|
|
|
|
|
|
|
22.04.26 - 16:30
|
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade? (24/7 Wall St.)
|
|
|
Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the stock to Buy from Neutral and raised his price target to $225 from $185. The call centers on a specific sequence of pipeline readouts Yee believes can move the stock meaningfully higher heading into 2027. This ... UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?...
|
|
|
|
|
22.04.26 - 14:00
|
Here Are Wednesday′s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Biogen, Cava Group, GitLab, Halliburton, Qualcomm, Seagate, Toast, and More (24/7 Wall St.)
|
|
|
Pre-Market Stock Futures: Futures are trading higher as we hit the midweek point. All major indices finished lower on Tuesday as the deadline for the ceasefire approached, amid threats to cancel talks between Iran and the United States. While the President did extend the ceasefire again, this time indefinitely, citing the “fractured government in Iran”, ... Here Are Wednesday's Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Biogen, Cava Group, GitLab, Halliburton, Qualcomm, Seagate, Toast, and More...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.04.26 - 13:33
|
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater China Region. With this agreement, Biogen now owns exclusive worldwide rights to felzartamab, which is currently being evaluated in global Phase 3 clinical studies across multiple immune-mediated diseases....
|
|
|
|
|
|
|
|
|
|
|
|